<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594018</url>
  </required_header>
  <id_info>
    <org_study_id>EMS2119 - FINLÂNDIA</org_study_id>
    <nct_id>NCT04594018</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia</brief_title>
  <official_title>National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Finlândia hair lotion association in&#xD;
      the treatment of androgenetic alopecia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in hair density.</measure>
    <time_frame>6 months</time_frame>
    <description>Digital phototrichogram evaluation of vertex area regarding the change from baseline in number of hairs after 6 months of treatment compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>FINLÂNDIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:&#xD;
1 tablet finasteride placebo, oral, once a day.&#xD;
1 mL Finlândia hair lotion, topical, twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minoxidil + finasteride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:&#xD;
1 tablet finasteride, oral, once a day.&#xD;
1 mL minoxidil hair lotion, topical, twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finlândia Association + finasteride placebo</intervention_name>
    <description>Finlândia association hair lotion + finasteride placebo</description>
    <arm_group_label>FINLÂNDIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minoxidil + finasteride</intervention_name>
    <description>Minoxidil hair lotion + Finasteride 1 mg</description>
    <arm_group_label>Minoxidil + finasteride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to confirm voluntary participation and agree to all trial purposes by signing&#xD;
             and dating the informed consent forms;&#xD;
&#xD;
          -  Men aged 18 years or over and less than or equal to 60 years with a diagnosis of&#xD;
             Androgenetic Alopecia grades IIIv to IV in the modified Norwood-Hamilton&#xD;
             classification, who have been using minoxidil 5% for at least 3 months and willing to&#xD;
             maintain the same style, approximate length and hair color throughout the test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the formula components used during the clinical trial;&#xD;
&#xD;
          -  History of alcohol and/or substance abuse within 2 years;&#xD;
&#xD;
          -  Participants with other concomitant dermatological diseases on the scalp, except for&#xD;
             mild seborrhoea dermatitis;&#xD;
&#xD;
          -  Participants with a history of surgical treatment for hair loss or shaved scalp;&#xD;
&#xD;
          -  Participants who used shampoo or topical solution containing ketoconazole, tar,&#xD;
             selenium, threonine or steroids in the last 2 weeks;&#xD;
&#xD;
          -  Participants who used 5α reductase inhibitors, such as finasteride and dutasteride, in&#xD;
             the last 12 months;&#xD;
&#xD;
          -  Participants using testosterone replacement therapy (TRT) or using&#xD;
             testosterone-containing gel;&#xD;
&#xD;
          -  Participants who used micro-infusion of medications on the skin (MMP), microneedling&#xD;
             or intradermotherapy on the scalp in the last 3 months;&#xD;
&#xD;
          -  Participants who have undergone radiation treatment for the scalp or chemotherapy in&#xD;
             the past year;&#xD;
&#xD;
          -  Participants with diseases that can affect hair growth;&#xD;
&#xD;
          -  Participants with a current medical history of cancer and / or cancer treatment in the&#xD;
             last 5 years;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>androgenetic alopecia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minoxidil</mesh_term>
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

